- Home
- FSM vs TVTX Comparison
FSM vs TVTX Comparison
Compare FSM & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSM
- TVTX
- Stock Information
- Founded
- FSM 1990
- TVTX 2008
- Country
- FSM Canada
- TVTX United States
- Employees
- FSM N/A
- TVTX N/A
- Industry
- FSM Precious Metals
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- FSM Basic Materials
- TVTX Health Care
- Exchange
- FSM Nasdaq
- TVTX Nasdaq
- Market Cap
- FSM 2.3B
- TVTX 1.5B
- IPO Year
- FSM N/A
- TVTX N/A
- Fundamental
- Price
- FSM $8.36
- TVTX $23.47
- Analyst Decision
- FSM Hold
- TVTX Strong Buy
- Analyst Count
- FSM 1
- TVTX 16
- Target Price
- FSM $8.00
- TVTX $35.20
- AVG Volume (30 Days)
- FSM 16.1M
- TVTX 2.7M
- Earning Date
- FSM 11-05-2025
- TVTX 10-30-2025
- Dividend Yield
- FSM N/A
- TVTX N/A
- EPS Growth
- FSM 7355.92
- TVTX N/A
- EPS
- FSM 0.50
- TVTX N/A
- Revenue
- FSM $1,187,211,000.00
- TVTX $333,865,000.00
- Revenue This Year
- FSM N/A
- TVTX $83.26
- Revenue Next Year
- FSM N/A
- TVTX $43.19
- P/E Ratio
- FSM $16.27
- TVTX N/A
- Revenue Growth
- FSM 46.81
- TVTX 87.94
- 52 Week Low
- FSM $4.13
- TVTX $11.89
- 52 Week High
- FSM $8.64
- TVTX $28.69
- Technical
- Relative Strength Index (RSI)
- FSM 69.51
- TVTX 64.09
- Support Level
- FSM $7.55
- TVTX $20.84
- Resistance Level
- FSM $7.97
- TVTX $28.69
- Average True Range (ATR)
- FSM 0.32
- TVTX 1.45
- MACD
- FSM 0.06
- TVTX 0.61
- Stochastic Oscillator
- FSM 78.79
- TVTX 55.14
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru. The company's segment consists of Mansfield, Sanu, Sango, Cuzcatlan, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d'Ivoire location.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.